Fabrication and production of conjugated neurotensin-silver nanoparticles and evaluation of its effect on pathophysiology of allergic asthma.

Abstract

Asthma, a respiratory tract disease, is characterized by inflammation and obstruction of airway. Inflammatory cells play a significant role in allergic asthma, and there is no complete cure for asthma. One of the new approaches in medicines is nanoparticle-base treatment. The aim of the current study is to introduce a new therapeutic approach in nano-medicine with neurotensin. Conjugated peptide nanoparticles were prepared and characterized, and then administrated to asthmatic mice. Airway hyperresponsiveness (AHR) test, broncho-alveolar lavage fluid (BALF) cells counting, cytokines level, and histopathology study were conducted. Treatment with peptide nanoparticles could control AHR, percentage of eosinophils in BALF, levels of interleukin 4 (IL-4), IL-5, and IL-33, peri-airways and perivascular eosinophilic inflammation. Producing and using of new peptide nano-drugs could introduce new therapeutic approach in controlling pathological-related mechanisms in allergic asthma.